Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose: The epidermal growth factor receptor (EGFR) is a key regulator of growth, differentiation, and survival of epithelial cancers. In a small subset of tumors, the presence of activating mutations within the ATP binding site confers increased susceptibility to gefitinib, a potent tyrosine kinase inhibitor of EGFR. Agents that can inhibit EGFR function through different mechanisms may enhance gefitinib activity in patients lacking these mutations. Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies. Experimental Design: In this study, we evaluated the effect of lovastatin on EGFR function and on gefitinib activity. Effects on EGFR function were analyzed by Western blot analysis using phosphospecific antibodies to EGFR, AKT, and extracellular signal-regulated kinase. Cytotoxic effects of lovastatin and/or gefitinib were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and flow cytometry. Results: Lovastatin treatment inhibited EGF-induced EGFR autophosphorylation by 24 hours that was reversed by the coadministration of mevalonate. Combining lovastatin and gefitinib treatments showed enhanced inhibition of AKT activation by EGF in SCC9 cells. The combination of 10 μmol/L lovastatin and 10 μmol/L gefitinib treatments showed cooperative cytotoxicity in all 8 squamous cell carcinomas, 4 of 4 non–small cell lung carcinoma and 4 of 4 colon carcinoma cell lines tested. Isobologram and flow cytometric analyses of three representative cell lines with wild-type EGFR ATP binding sites confirmed that this combination was synergistic inducing a potent apoptotic response. Conclusions: Taken together, these results show that targeting the mevalonate pathway can inhibit EGFR function. They also suggest the potential utility of combining these clinically relevant therapeutic approaches.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, inhibition of the mevalonate pathway exerts a strong impact on several oncogenic signaling pathways (Mantha et al., 2005).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Mantha et al., 2005
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 9×
“pronounced in tumor cells that harbored mutations in the ATP binding pocket of the EGFR tyrosine kinase domain (10, 11), we determined the mutational status of this region in 10 representative cell lines used in this study.”
BackgroundMethodInfluentialRegulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Cited by
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
“Statins have been shown to inhibit ligandinduced EGFR activation and downstream AKT signaling, which can be reversed by exogenousGGPP (88, 89).”
BackgroundStatins and cancer: Current and future prospects
Osmak, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.011 · Cited by 189
Metadata
- Authors
- Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J.
- Affiliations
- 1Centre for Cancer Therapeutics and
- 2Medical Oncology,
- University of Ottawa (CA)
- Venue
- Clinical Cancer Research
- Published
- 2005-03-15
- Volume
- 11
- Issue
- 6
- Pages
- 2398-2407
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2113341349
- Cited by
- 101
- References
- 35
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 7 · 2014: 5 · 2013: 7 · 2012: 5
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- mevalonate pathway, epidermal growth factor receptor, lovastatin, gefitinib, combination therapy, EGFR autophosphorylation, Akt activation, squamous cell carcinoma, non-small cell lung cancer, colon cancer, apoptosis, drug synergy, mevalonate
- MeSH terms
- Gefitinib, Adenosine Triphosphate, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Colonic Neoplasms, Drug Synergism, Enzyme Inhibitors, Epidermal Growth Factor, Humans, Lovastatin, Lung Neoplasms, Mevalonic Acid, Mutation, Phosphorylation, Quinazolines, Tumor Cells, Cultured, Signal Transduction, Apoptosis, Mitogen-Activated Protein Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1951
- The paper
- Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005). Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.